REMARKS

The application is objected to as failing to comply with the requirements of 37 C.F.R. §§1.821-1.825 governing patent applications with nucleotide and/or amino acid sequences. In particular, the Notice indicates that the computer readable form (CRF) of the Sequence Listing filed on October 27, 2006 has been found to be incomplete. Accordingly, a substitute CFR of the Sequence Listing, substitute hard (paper) copy of the Sequence Listing and a statement pursuant to the applicable provisions of 37 C.F.R. §§1.821-1.825 are required.

Accordingly, Applicants submit herewith a substitute CFR of the Sequence Listing, substitute hard (paper) copy of the Sequence Listing (pages 1-28) and the statement required by the applicable provisions of 37 C.F.R. §§1.821-1.825. In addition, the application has been amended to direct entry of the substitute Sequence Listing (pages 1-28).

If a telephone conversation with Applicants' attorney would help expedite the further processing of the application, the Examiner is urged to call the undersigned attorney at (617) 517-5580.

Dated: September 20, 2007

Respectfully submitted,

Melissa Hunter-Ensor, Ph.D.

Registration No.: 55,289

EDWARDS ANGELL PALMER & DODGE LLP

Docket No.: 60261(49946)

P.O. Box 55874

Boston, Massachusetts 02205

(617) 517-5580

Attorneys/Agents For Applicants

BOS2_632316.1